Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome

Cristiana Vitale, Giuseppe Mercuro, Carlotta Castiglioni, Alessandra Cornoldi, Arianna Tulli, Massimo Fini, Maurizio Volterrani, Guiseppe M C Rosano

Research output: Contribution to journalArticle

Abstract

Background: Metabolic syndrome is a cluster of common cardiovascular risk factors that includes hypertension and insulin resistance. Hypertension and diabetes mellitus are frequent comorbidities and, like metabolic syndrome, increase the risk of cardiovascular events. Telmisartan, an antihypertensive agent with evidence of partial peroxisome proliferator-activated receptor activity-gamma (PPARγ) activity, may improve insulin sensitivity and lipid profile in patients with metabolic syndrome. Methods: In a double-blind, parallel-group, randomized study, patients with World Health Organization criteria for metabolic syndrome received once-daily doses of telmisartan (80 mg, n = 20) or losartan (50 mg, n = 20) for 3 months. At baseline and end of treatment, fasting and postprandial plasma glucose, insulin sensitivity, glycosylated haemoglobin (HBA1c) and 24-hour mean systolic and diastolic blood pressures were determined. Results: Telmisartan, but not losartan, significantly (p <0.05) reduced free plasma glucose, free plasma insulin, homeostasis model assessment of insulin resistance and HbAic. Following treatment, plasma glucose and insulin were reduced during the oral glucose tolerance test by telmisartan, but not by losartan. Telmisartan also significantly reduced 24-hour mean systolic blood pressure (p <0.05) and diastolic blood pressure (p <0.05) compared with losartan. Conclusions: As well as providing superior 24-hour blood pressure control, telmisartan, unlike losartan, displayed insulin-sensitizing activity, which may be explained by its partial PPARγ activity.

Original languageEnglish
Article number6
JournalCardiovascular Diabetology
Volume4
DOIs
Publication statusPublished - May 15 2005

Keywords

  • Angiotensin II receptor blockers
  • Hypertension
  • Losartan
  • Metabolic syndrome
  • Telmisartan

ASJC Scopus subject areas

  • Medicine(all)
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Metabolic effect of telmisartan and losartan in hypertensive patients with metabolic syndrome'. Together they form a unique fingerprint.

  • Cite this